EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Resistance development in KPC-producing Klebsiella pneumoniae under ceftazidime/avibactam-meropenem pressure: KPC-2 Ω-loop mutations attenuate avibactam efficacy

Fu-Hao Li iD, Mei Zheng, Gong-Mei Zhong, Xue-Mei He, Meng-Zhen Hu, Xu Kuang, Jing-Jing Wu, Chang-Min Li, Jia-Ning Wang, Xiao-Yu Zhou, Yang Yu iD

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.00356-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Fu-Hao Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Laboratory for Lingnan Modern Agriculture, National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, Co…. Hauptthemen laut MEDLINE: Ceftazidime, Klebsiella pneumoniae, Azabicyclo Compounds, beta-Lactamases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Innovative Research Groups of the National Natural Science Foundation of China, Guangdong provincial key research and development program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ceftazidime/avibactam (CAZ-AVI, CZA) combination is a potent agent against KPC-producing Klebsiella pneumoniae (KPC-Kp) infections, but resistance readily emerges via KPC mutations that restore carbapenem susceptibility. Previous studies have shown that the CZA-meropenem (MEM) combination exhibits favorable therapeutic efficacy by exploiting this collateral sensitivity. Here, we investigated in vitro how this adjunctive combination impacts resistance evolution in KPC-Kp and delineated the underlying molecular mechanisms. Resistance evolution in 26 KPC-Kp isolates was selected by multipassaging under dual CZA-MEM pressure. The underlying resistant mechanisms were systematically dissected by integrating MICs, enzyme kinetics, molecular docking, and molecular dynamics simulations. In contrast to CZA alone, the CZA-MEM combination significantly suppressed resistance development, but five strains still adapted. Under dual-drug selection, mutations arose solely within KPC but were restricted to the Ω loop. Kinetic analysis showed that these mutations drive CZA resistance (R164S variants chiefly by increasing ceftazidime hydrolysis, R164L variants by weakening AVI inhibition, and D179Y by both mechanisms) while simultaneously restoring MEM susceptibility (all variants reduced MEM hydrolysis). Importantly, every mutant elevated the AVI IC 50 , suggesting this is the optimal evolutionary path for KPC-Kp under CZA-MEM pressure. Mechanistic studies reveal that R164L/T243S mutations destabilize the Ω loop to reposition Ser70 at the active site and confer AVI resistance by impairing acylation, destabilizing the enzyme-inhibitor complex, and potentially accelerating deacylation. Our study provides actionable clues for positioning and deploying different β-lactam agents in the treatment of KPC-Kp infections. IMPORTANCE The global rise of KPC-producing Klebsiella pneumoniae (KPC-Kp) severely limits available therapeutic options, underscoring the urgent need for strategies that curb resistance evolution. The ceftazidime/avibactam-meropenem combination exploits collateral sensitivity to suppress resistance development, yet adaptive mutations still emerge. However, the mechanisms underlying resistance development under dual-drug pressure remain unclear. This study focused on Ω-loop mutations in KPC under dual-drug pressure, revealing that these mutations concurrently enhance avibactam resistance and restore carbapenem susceptibility, although the potential contribution of additional genetic alterations cannot be fully excluded. These findings offer critical insights for optimizing combination therapies and monitoring resistance mechanisms during treatment of KPC-Kp infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeKlebsiella pneumoniaeAzabicyclo Compoundsbeta-LactamasesAnti-Bacterial AgentsBacterial ProteinsDrug Resistance, Multiple, BacterialDrug CombinationsKlebsiella InfectionsMutationMicrobial Sensitivity TestsHumansThird Generation CephalosporinsMolecular Docking Simulation

Stichwörter der Autor:innen

KPCKPC-producing Klebsiella pneumoniaeavibactam resistanceceftazidime/avibactamcollateral sensitivitymeropenemΩ-loop mutations

Substanzen

CeftazidimeAzabicyclo Compoundsavibactam, ceftazidime drug combinationDrug Combinationsbeta-LactamasesAnti-Bacterial AgentsavibactamBacterial ProteinsThird Generation Cephalosporinsbeta-lactamase KPC-2, Klebsiella pneumoniae

Autor:innen und Institutionen

  • Guangdong Laboratory for Lingnan Modern Agriculture, National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Gua…
  • State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, China.

ORCID-Profile: Fu-Hao Li, Yang Yu

Förderung

  • National Key Research and Development Program of China
  • Innovative Research Groups of the National Natural Science Foundation of China
  • Guangdong provincial key research and development program
  • Specific university discipline construction project
  • 111 center

Zitieren

APA

Li, F. H., Zheng, M., Zhong, G. M., He, X. M., Hu, M. Z., Kuang, X., Wu, J. J., Li, C. M., Wang, J. N., Zhou, X. Y., & Yu, Y. (2026). Resistance development in KPC-producing Klebsiella pneumoniae under ceftazidime/avibactam-meropenem pressure: KPC-2 Ω-loop mutations attenuate avibactam efficacy. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00356-26

Vancouver

Li FH, Zheng M, Zhong GM, He XM, Hu MZ, Kuang X, et al. Resistance development in KPC-producing Klebsiella pneumoniae under ceftazidime/avibactam-meropenem pressure: KPC-2 Ω-loop mutations attenuate avibactam efficacy. Microbiology Spectrum. 2026. doi:10.1128/spectrum.00356-26

BibTeX
@article{Li2026,
  author = {Li, Fu-Hao and Zheng, Mei and Zhong, Gong-Mei and He, Xue-Mei and Hu, Meng-Zhen and Kuang, Xu and Wu, Jing-Jing and Li, Chang-Min and Wang, Jia-Ning and Zhou, Xiao-Yu and Yu, Yang},
  title = {Resistance development in KPC-producing Klebsiella pneumoniae under ceftazidime/avibactam-meropenem pressure: KPC-2 Ω-loop mutations attenuate avibactam efficacy},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.00356-26}
}
Kostenlos starten →